More articles from Heart Failure Update
- ACE inhibitors vs ARBs: Is one class better for heart failure?
A patient who apparently cannot tolerate ACE inhibitors presents with worsening heart failure. What should be the next step?
- Improving the care of patients dying of heart failure
Too many heart failure patients die in pain, short of breath, and with too much left unsaid. We can do better for them.
- Management of asymptomatic left ventricular dysfunction
Heart failure can have an insidious onset, and the best time to intervene with ACE inhibitors and beta-blockers is early.
- Heart failure disease management: A team approach
To treat heart failure effectively you need a team and you need a plan. In short, you need a program.
- The current role of amiodarone in patients with congestive heart failure
Amiodarone is the antiarrhythmic agent of choice for patients with congestive heart failure, but its clinical benefit remains unproved.
- Our new understanding of heart failure: The role of beta-blockers in treatment
Beta-blockers can stop the downward spiral of heart failure by improving the biology of the myocyte. With an illustration showing the abnormal remodeling process in heart failure.
- The heart failure pandemic: Changing patterns, costs, and treatment strategies
As the definition of heart failure changes, new treatment strategies are needed to control costs and reduce suffering.
- New Series: Heart Failure Update
Heart failure is going to be every physician’s problem, regardless of specialty.